Trasicor 80mg tablets

Pays: Royaume-Uni

Langue: anglais

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingrédients actifs:

Oxprenolol hydrochloride

Disponible depuis:

Amdipharm Plc

Code ATC:

C07AA02

DCI (Dénomination commune internationale):

Oxprenolol hydrochloride

Dosage:

80mg

forme pharmaceutique:

Oral tablet

Mode d'administration:

Oral

classe:

No Controlled Drug Status

Type d'ordonnance:

Valid as a prescribable product

Descriptif du produit:

BNF: 02040000; GTIN: 5060064170441

Notice patient

OXPRENOLOL 20 MG, 40 MG AND 80 MG TABLETS
OXPRENOLOL HYDROCHLORIDE
GB 727-0382-APIL
SOVEREIGN
M
E
D
I
C
A
L
READ ALL OF THIS LEAFLET CAREFULLY
BEFORE YOU START TAKING THIS
MEDICINE.
-
Please keep this leaflet. You may
need to read it again.
-
If you have any further questions,
ask your doctor or pharmacist.
-
This medicine has been prescribed
for you. Do not pass it on to others.
It may harm them, even if their
symptoms are the same as yours.
-
If any of the side effects becomes severe, or if you notice any
side effects not listed in this leaflet, please tell your doctor or
pharmacist.
IN THIS LEAFLET:
1.
What Oxprenolol Tablets are and what they are used for
2.
Before you take Oxprenolol Tablets
3.
How to take Oxprenolol Tablets
4.
Possible side effects
5.
How to store Oxprenolol Tablets
6.
Further information
1.
WHAT OXPRENOLOL TABLETS ARE AND WHAT THEY ARE
USED FOR
The name of your medicine is Oxprenolol 20 mg, 40 mg or 80 mg
Tablets.
Oxprenolol
Tablets
contain
the
active
ingredient
oxprenolol
hydrochloride.
Oxprenolol hydrochloride belongs to a group of medicines called
beta-blockers.
Oxprenolol is used to treat high blood pressure and to reduce or
prevent chest pain (angina). It is also used to treat some heart
disorders such as irregular heart beat and to relieve the symptoms
of anxiety.
2.
BEFORE YOU TAKE OXPRENOLOL TABLETS
DO NOT TAKE OXPRENOLOL TABLETS IF YOU:
•
are ALLERGIC to OXPRENOLOL, any other beta-blockers, or any of
the other ingredients of Oxprenolol Tablets (allergic reactions
include mild symptoms such as itching and/or rash. More
severe symptoms include swelling of the face, lips, tongue
and/or throat with difficulty in swallowing or breathing);
•
have a history of asthma or wheezing attacks;
•
have any HEART problems (e.g. heart failure, cardiogenic
shock);
•
have an untreated TUMOUR of the adrenal gland
(phaeochromocytoma);
•
have any heart rhythm disorders (sick-sinus syndrome);
•
have a very LOW PULSE RATE (less than 50 beats per minute);
•
have Prinzmetal’s angina (a spec

Résumé des caractéristiques du produit

1. NAME OF THE MEDICINAL PRODUCT
Trasicor 80 mg Tablets.
Oxprenolol 80 mg Tablets.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 80 mg of oxprenolol hydrochloride.
Excipients with known effect:
Sodium starch glycollate
(21.3 mg/ tablet)
For the full list of excipients, see section 6.1
3. PHARMACEUTICAL FORM
Film-coated tablets.
Light yellow, round, biconvex, film-coated tablets, impressed OXP 80
on one face and no
marking on the other.
4.1 THERAPEUTIC INDICATIONS
Trasicor Tablets are indicated in adults for the treatment of:
Angina Pectoris: For long-term prophylactic use (if necessary nitrates
should be employed for
alleviating acute attacks).
Hypertension: As monotherapy or for use in combination with other
antihypertensives, e.g. with a
diuretic, peripheral vasodilator, calcium channel blocker or ACE
inhibitor.
Disturbances of cardiac rhythm: Especially supraventricular
tachycardia, atrial fibrillation and
digitalis-induced arrhythmias, ventricular tachycardia.
Short-term relief of functional cardiovascular disorders due to
adrenergic hyperactivity: Such as
cardiac neurosis, hyperkinetic heart syndrome and anxiety-induced
cardiovascular disorders.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_ _
The dosage should be individualised. Before raising the dosage, the
heart rate at rest should
always be checked. If it is 50-55 beats/min, the dosage should not be
increased, see
contraindications.
If the maximum recommended dose is insufficient to produce the desired
response appropriate
combined therapy should be considered.
When discontinuing prolonged treatment with a beta-blocker, the
medication should not be
interrupted abruptly, but withdrawn gradually.
Higher doses using conventional Trasicor Tablets may be administered
in two or more divided
doses.
Elderly _ _
No special dosage regime is necessary but concurrent hepatic
insufficiency should be taken into
account.
_Paediatric population _
No adequate experience has been acquired on the use of Trasicor
Tablets in children.
Adults
_Hypert